Suppliers and packagers for THALITONE

THALITONE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Casper Pharma Llc	THALITONE	chlorthalidone	TABLET;ORAL	019574	NDA	Casper Pharma LLC	70199-001-01	100 TABLET in 1 BOTTLE (70199-001-01)	2019-11-27
Casper Pharma Llc	THALITONE	chlorthalidone	TABLET;ORAL	019574	NDA	Casper Pharma LLC	70199-001-30	30 TABLET in 1 BOTTLE (70199-001-30)	2019-11-27
Casper Pharma Llc	THALITONE	chlorthalidone	TABLET;ORAL	019574	NDA	Casper Pharma LLC	70199-017-01	100 TABLET in 1 BOTTLE (70199-017-01)	2019-11-27
Casper Pharma Llc	THALITONE	chlorthalidone	TABLET;ORAL	019574	NDA	Casper Pharma LLC	70199-017-30	30 TABLET in 1 BOTTLE (70199-017-30)	2019-11-27

Suppliers for the Pharmaceutical Drug: Thalitone

Last updated: July 27, 2025

Introduction

Thalitone, the brand name for the generic drug chlorthalidone, is a potent diuretic primarily used to manage hypertension and edema associated with congestive heart failure, renal disease, or hepatic cirrhosis. As a stalwart in the antihypertensive class, its widespread clinical use has generated a broad supplier landscape. This article offers an in-depth analysis of the key suppliers for Thalitone, examining manufacturing sources, distribution channels, and market dynamics shaping supply chain stability.

---

Manufacturers of Thalitone (Chlorthalidone)

While Thalitone is marketed under the AbbVie brand, its active pharmaceutical ingredient (API), chlorthalidone, is produced by multiple suppliers globally. AbbVie retains exclusive rights to market Thalitone in numerous regions; however, the APIs may originate from other manufacturers that supply generic formulations or raw materials for further processing.

1. Original Manufacturer and Patent Status

AbbVie's Thalitone was introduced in the late 20th century, and its patent protection has long expired, opening the market to generics. Consequently, the production of chlorthalidone is now licensed to various pharmaceutical companies worldwide, increasing market competition and diversifying supply sources.

2. Major API Suppliers

The API manufacturing landscape for chlorthalidone encompasses several reputable firms:

• Synthesis Pharma Inc. (India): A prominent generic API producer, Synthesis Pharma supplies chlorthalidone API to multiple markets, adhering to stringent quality standards such as ISO 9001 and cGMP guidelines. Their production capacity and quality control processes enable large-scale distribution.

• Hetero Labs Limited (India): Recognized globally for its robust portfolio of active pharmaceutical ingredients, Hetero provides chlorthalidone APIs to both generic and branded drug manufacturers.

• Ming Tao Pharmaceutical (China): Engaged in the synthesis of diuretics, Ming Tao supplies API bulk products to international markets, with increasing OEM partnerships.

• Teva Pharmaceuticals (Israel): Although primarily a generic drug manufacturer, Teva develops its own APIs, including chlorthalidone, for internal use and external licensing.

• Sun Pharma (India): As one of the world's largest generic pharmaceutical companies, Sun Pharma produces chlorthalidone APIs for a broad distribution network.

3. Contract Manufacturing Organizations (CMOs)

Some companies do not produce APIs in-house but partner with CMOs to synthesize chlorthalidone:

• Recipharm (Sweden): Provides CMO services for diuretics, including chlorthalidone, emphasizing quality compliance.

• Dr. Reddy's Laboratories (India): Engages in API synthesis via third-party manufacturers, ensuring cost-effective supply chains.

---

Distribution and Supply Chain Dynamics

1. Regional Suppliers and Regulatory Approval

Regions such as North America, Europe, and Asia exhibit differing supplier ecosystems:

• North America: The primary supply chain involves API imported predominantly from India and China into licensed US and Canadian manufacturing facilities, followed by formulation and packaging.

• Europe: Local and imported APIs, mainly from Indian and Chinese manufacturers, supply European generic companies’ production lines, subject to European Medicines Agency (EMA) approvals.

• Asia-Pacific: Dominant manufacturing hubs, India and China, serve as primary sources for both APIs and finished formulations, with local distributors favoring domestic sourcing due to cost advantages.

2. Market Entry Barriers and Regulatory Considerations

Suppliers must navigate complex regulatory landscapes, including FDA, EMA, and equivalent agencies, which impose rigorous Quality, Safety, and Efficacy standards. Certificates of Suitability (CEP) from the EDQM or Drug Master Files (DMFs) provide essential documentation that facilitates licensing and approval processes. These hurdles influence supplier selection and supply reliability.

3. Challenges in Supply Chain Stability

Fluctuations in API availability stem from manufacturing disruptions, geopolitical issues, raw material shortages, and global health crises like COVID-19. These factors can lead to delayed deliveries or shortages of Thalitone and its generics. Companies mitigate risks by diversifying supplier bases and establishing multiple sourcing contracts.

---

Key Players in Thalitone Supply Chain

Supplier Category	Notable Companies	Key Characteristics
API Manufacturers (India/China)	Synthesis Pharma, Hetero Labs, Ming Tao Pharma	Large-scale, cost-effective, compliant with international standards
CROs & CMOs	Recipharm, Dr. Reddy's Laboratories	Contracted manufacturers ensuring scalable production
Finished Dosage Form Suppliers	Teva, Sun Pharma, Lupin, Novartis (regional)**	Final product manufacturers and distributors
Distributors & Wholesalers	McKesson, Cardinal Health, AmerisourceBergen	Global and regional distribution networks

---

Market Trends and Implications for Suppliers

• Growing Demand for Generics: The expiration of patents has catalyzed a surge in generic chlorthalidone production, intensifying competition among suppliers.

• Regulatory Stringency: Suppliers adhering to international standards will maintain competitive advantage, given rising quality expectations.

• Supply Chain Resilience: Diversified sourcing and strategic alliances are critical amid global disruptions, especially with API sourcing from India and China.

• Emerging Markets: Expansion into emerging markets necessitates partnerships with local distributors and compliance with regional regulatory frameworks.

---

Conclusion

The supply landscape for Thalitone (chlorthalidone) is characterized by a diversified network of API manufacturers, contract manufacturing organizations, and finished dosage producers spanning North America, Europe, and Asia. The global nature of supply chains underscores the importance of regulatory compliance, quality assurance, and strategic sourcing in maintaining a stable supply of this essential antihypertensive agent. As market dynamics evolve, companies that prioritize vendor diversification, adhere to stringent quality standards, and adapt to regulatory changes will position themselves favorably in the competitive landscape.

---

Key Takeaways

• The patent expiration of Thalitone has led to a proliferation of generic API suppliers, notably in India and China.

• API manufacturing relies on reputable firms like Hetero Labs, Synthesis Pharma, and Ming Tao Pharma, with extensive supply capacities.

• Global supply chain disruptions necessitate strategic diversification and quality compliance to ensure consistent availability.

• Regulatory frameworks such as EMA, FDA, and EDQM guidelines are critical considerations for supplier qualification and product approval.

• Market trends favor cost-effective, high-quality suppliers with scalable operations and strong compliance histories.

---

FAQs

Q1: Who are the leading API suppliers for chlorthalidone used in Thalitone?
A: Major API suppliers include Indian firms such as Hetero Labs and Sun Pharma, as well as Chinese manufacturers like Ming Tao Pharmaceutical, all adhering to international quality standards.

Q2: How does regulatory approval impact supplier selection for Thalitone?
A: Suppliers must provide regulatory documentation like CEPs and DMFs demonstrating compliance with authorities such as the FDA and EMA, which influence approval timelines and supply stability.

Q3: Are there geopolitical factors affecting the supply of Thalitone?
A: Yes. Trade policies, tariffs, and geopolitical tensions, especially between Western countries and China or India, can impact API supply chains and cost structures.

Q4: What risks threaten the supply chain for Thalitone?
A: Disruptions stem from manufacturing issues, raw material shortages, geopolitical conflicts, and global health crises, potentially leading to shortages.

Q5: What strategies do companies use to mitigate supply chain risks for Thalitone?
A: Diversifying API sources, establishing multiple supplier relationships, maintaining safety stock, and complying with international standards are common approaches.

---

References

1. [1] U.S. Food and Drug Administration. (2022). Drug Master Files (DMFs).
2. [2] European Directorate for the Quality of Medicines & HealthCare (EDQM). (2023). Certificates of Suitability.
3. [3] IMS Health. (2022). Global Pharmaceutical Market Data.
4. [4] Hetero Labs Ltd. Corporate Website. (2023). API Portfolio.
5. [5] Sun Pharmaceutical Industries Ltd. Annual Report. (2022).